 |
市場調查報告書
商品編碼
1550561
小分子藥物發現的全球市場：按治療領域、製程、最終用戶和地區分類Small Molecule Drug Discovery Market, By Therapeutic Area, By Process, By End User (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic and Research Institutes, Others), By Geography |
||||||
預計2024年全球小分子藥物發現市場規模將達561億美元，2024年至2031年複合年成長率為8.6%，2031年將達到1000.1億美元。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年 | 2023年 | 2024年市場規模 | 561億美元 |
| 實際資料 | 2019-2023 | 預測期 | 2024-2031 |
| 預測 2024-2031 年複合年成長率： | 8.60% | 2031 年金額預測 | 1000億美元 |
小分子藥物比大分子藥物具有更高的生物有效性和更好的組織滲透性等優勢。它也可以透過多種途徑給藥，包括口服和靜脈注射。製藥和生物技術公司對研發活動的投資增加以及對學名藥的需求不斷成長正在推動市場成長。然而，臨床試驗期間的高退出率可能會阻礙市場成長。此外，一些新興企業正在利用人工智慧和機器學習等技術來增強藥物發現過程並降低失敗率。
市場動態：
全球小分子藥物發現市場的成長是由藥品研發支出增加、學名藥需求增加以及合約研究和製造服務行業的成長所推動的。然而，候選藥物的高臨床失敗率和嚴格的監管可能會阻礙市場成長。開拓人工智慧和機器學習在藥物開發中的應用為市場參與者提供了新的機會。製藥公司擴大採用此類技術來加快發現過程並最佳化分子設計。這樣可以降低離職率。目前，由於大公司的存在和高醫療保健支出，北美在市場上佔據主導地位。預計亞太地區將在不久的將來成為成長最快的市場。
本研究的主要特點
本報告對全球小分子藥物發現市場進行了詳細分析，並以2023年為基準年估計了預測期（2024-2031年）的市場規模（十億美元）和年複合成長率（CAGR%）。被出版了。
它還揭示了各個細分市場的潛在商機，並解釋了該市場中有吸引力的投資提案的矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
它根據公司亮點、產品系列、主要亮點、財務表現和策略等參數，介紹了全球小分子藥物發現市場的主要企業。
主要企業包括輝瑞、百時美施貴寶公司、默克、安捷倫科技、阿斯特捷利康、勃林格殷格翰和查爾斯河實驗室。
該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
全球小分子藥物發現市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球小分子藥物發現市場的各種策略矩陣，將有助於相關人員做出決策。
目錄
第1章 研究目的與前提
- 研究目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章市場動態、法規及趨勢分析
- 市場動態
- 影響分析
- 主要亮點
- 監管場景
- 產品發布/核准
- PEST分析
- 波特的分析
- 併購場景
第4章全球小分子藥物發現市場，依治療領域，2019-2031（美元）
- 腫瘤學
- 中樞神經系統
- 循環系統
- 呼吸系統
- 代謝性疾病
- 胃腸道
- 其他
第5章 全球小分子藥物發現市場，依流程分類，2019-2031 年（美元）
- 目標ID/檢驗
- 熱門生成和選擇
- 線索識別
- 先導藥物最適化
第6章 全球小分子藥物發現市場，以最終用戶分類，2019-2031 年（美元）
- 製藥公司
- 生技公司
- 合約研究組織（CRO）
- 學術研究所
- 其他
第7章全球小分子藥物發現市場，按地區，2019-2031（美元）
- 拉丁美洲
- 歐洲
- 亞太地區
- 中東
第8章 競爭格局
- Pfizer Inc.
- Merck & Co., Inc.
- Novartis AG
- Johnson & Johnson
- AstraZeneca PLC
- GlaxoSmithKline plc
- Bristol Myers Squibb
- Eli Lilly and Company
- Gilead Sciences, Inc.
- Teva Pharmaceuticals
- Boehringer Ingelheim GmbH
- Thermo Fisher Scientific Inc.
- Charles River Laboratories
- Labcorp Drug Development
- Agilent Technologies Inc.
- ICON Plc
- Eurofins Discovery
- Immunocure Inc.
- Acacia Pharma Group
- 4SC AG
第9章 分析師建議
- 命運之輪
- 分析師觀點
- 一致的機會圖
第10章 參考文獻與調查方法
- 參考
- 調查方法
- 出版商
Global small molecule drug discovery market is estimated to be valued at USD 56.10 Bn in 2024 and is expected to reach USD 100.01 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.6% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 56.10 Bn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 8.60% | 2031 Value Projection: | US$ 100.01 Bn |
Small molecule drugs have advantages over large molecule drugs such as higher oral bioavailability and better tissue penetration. These can be administered via various routes including oral, intravenous and others. Growing investment in R&D activities by pharmaceutical and biotech companies coupled with rising demand for generics can drive the market growth. However, high attrition rates during clinical trials can hamper the market growth. Several startups also leverage technologies such as artificial intelligence and machine learning to enhance the drug discovery process and reduce failure rates.
Market Dynamics:
Global small molecule drug discovery market growth is driven by rising pharmaceutical R&D spending, increasing demand for generic drugs, and growth of contract research and manufacturing services industries. However, high clinical failure rates of drug candidates and stringent regulations can hamper the market growth. Growing application of AI and machine learning in drug development offers new opportunities for the market players. Pharma companies are increasingly adopting such technologies to speed up the discovery process and optimize molecular designs. This can lower attrition rates. North America dominates the market currently, owing to presence of major players and high healthcare expenditure. Asia Pacific is anticipated to emerge as the fastest growing market in the near future.
Key features of the study:
This report provides in-depth analysis of the global small molecule drug discovery market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global small molecule drug discovery market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer, Bristol-Myers Squibb Company, Merck, Agilent Technologies, AstraZeneca, Boehringer Ingelheim, Charles River Laboratories
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global small molecule drug discovery market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global small molecule drug discovery market
Detailed Segmentation-
- Therapeutic Area Insights (Revenue, USD, 2019 - 2031)
- Oncology
- Central Nervous System
- Cardiovascular
- Respiratory
- Metabolic Disorders
- Gastrointestinal
- Others
- Process Insights (Revenue, USD, 2019 - 2031)
- Target ID/Validation
- Hit Generation and Selection
- Lead Identification
- Lead Optimization
- End User Insights (Revenue, USD, 2019 - 2031)
- Pharmaceutical Companies
- Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic and Research Institutes
- Others
- Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- Merck & Co., Inc.
- Novartis AG
- Johnson & Johnson
- AstraZeneca PLC
- GlaxoSmithKline plc
- Bristol Myers Squibb
- Eli Lilly and Company
- Gilead Sciences, Inc.
- Teva Pharmaceuticals
- Boehringer Ingelheim GmbH
- Thermo Fisher Scientific Inc.
- Charles River Laboratories
- Labcorp Drug Development
- Agilent Technologies Inc.
- ICON Plc
- Eurofins Discovery
- Immunocure Inc.
- Acacia Pharma Group
- 4SC AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Small Molecule Drug Discovery Market, By Therapeutic Area
- Global Small Molecule Drug Discovery Market, By Process
- Global Small Molecule Drug Discovery Market, By End User
- Global Small Molecule Drug Discovery Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Small Molecule Drug Discovery Market, By Therapeutic Area, 2019-2031, (USD)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020- 2031
- Segment Trends
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Central Nervous System
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Cardiovascular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Respiratory
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Metabolic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Gastrointestinal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
5. Global Small Molecule Drug Discovery Market, By Process, 2019-2031, (USD)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Target ID/Validation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Hit Generation and Selection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Lead Identification
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Lead Optimization
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
6. Global Small Molecule Drug Discovery Market, By End User, 2019-2031, (USD)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Pharmaceutical Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Contract Research Organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Academic and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
7. Global Small Molecule Drug Discovery Market, By Region, 2019 - 2031, (USD)
- Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, (USD)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, (USD)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Therapeutic Area, 2019 - 2031, (USD)
- Market Size and Forecast, By Process, 2019 - 2031, (USD)
- Market Size and Forecast, By End User, 2019 - 2031, (USD)
- Market Size and Forecast, By Country, 2019 - 2031, (USD)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Therapeutic Area, 2019 - 2031, (USD)
- Market Size and Forecast, By Process, 2019 - 2031, (USD)
- Market Size and Forecast, By End User, 2019 - 2031, (USD)
- Market Size and Forecast, By Country, 2019 - 2031, (USD)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Therapeutic Area, 2019 - 2031, (USD)
- Market Size and Forecast, By Process, 2019 - 2031, (USD)
- Market Size and Forecast, By End User, 2019 - 2031, (USD)
- Market Size and Forecast, By Country, 2019 - 2031, (USD)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Therapeutic Area, 2019 - 2031, (USD)
- Market Size and Forecast, By Process, 2019 - 2031, (USD)
- Market Size and Forecast, By End User, 2019 - 2031, (USD)
- Market Size and Forecast, By Country, 2019 - 2031, (USD)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Therapeutic Area, 2019 - 2031, (USD)
- Market Size and Forecast, By Process, 2019 - 2031, (USD)
- Market Size and Forecast, By End User, 2019 - 2031, (USD)
- Market Size and Forecast, By Country, 2019 - 2031, (USD)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Therapeutic Area, 2019 - 2031, (USD)
- Market Size and Forecast, By Process, 2019 - 2031, (USD)
- Market Size and Forecast, By End User, 2019 - 2031, (USD)
- Market Size and Forecast, By Country/Sub-region, 2019 - 2031, (USD)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences, Inc.
- Teva Pharmaceuticals
- Boehringer Ingelheim GmbH
- Thermo Fisher Scientific Inc.
- Charles River Laboratories
- Labcorp Drug Development
- Agilent Technologies Inc.
- ICON Plc
- Eurofins Discovery
- Immunocure Inc.
- Acacia Pharma Group
- 4SC AG
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
